报价延迟最少15分钟:2025/07/15 13:17 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
18.0536 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.84/0.88
|
|
企业价值
4.54B
|
| 资产负债 |
|
每股账面净值
1.56
|
| 现金流量 |
|
现金流量率
0.02
|
| 损益表 |
|
收益
426.45M
|
|
每股收益
0.87
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/15 13:17 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and othersat risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions tocertain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States. |
